Epigenetic Modification of the Glucocorticoid Receptor Gene Is Linked to Traumatic Memory and Post-Traumatic Stress Disorder Risk in Genocide Survivors

Vanja Vukojevic,1,2 Iris-T. Kolassa,3 Matthias Fastenrath,1,4 Leo Gschwind,1,4 Klara Spalek,1,4 Annette Milnik,1,5 Angela Heck,1,5,6 Christian Vogler,1,5,6 Sarah Wilker,3 Philippe Demougin,1,2 Fabian Peter,1,2 Erika Atucha,7 Attila Stetak,1,5 Benno Roozendaal,7 Thomas Elbert,8 Andreas Papassotiropoulos,1,2,5,6 and Dominique J.-F. de Quervain4,5,6

1Department of Psychology, Division of Molecular Neuroscience, University of Basel, CH-4055 Basel, Switzerland, 2Department Biozentrum, Life Sciences Training Facility, University of Basel, CH-4056 Basel, Switzerland, 3Clinical & Biological Psychology, Institute of Psychology and Education, University of Ulm, D-89069 Ulm, Germany, 4Department of Psychology, Division of Cognitive Neuroscience, University of Basel, CH-4055 Basel, Switzerland, 5Psychiatric University Clinics, University of Basel, CH-4012 Basel, Switzerland, 6Transfaculty Research Platform, University of Basel, CH-4055 Basel, Switzerland, 7Department of Cognitive Neuroscience and Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, 6525 EZ Nijmegen, Netherlands, and 8Clinical Psychology and Neuropsychology, University of Konstanz, D-78464 Konstanz, Germany

Recent evidence suggests that altered expression and epigenetic modification of the glucocorticoid receptor gene (NR3C1) are related to the risk of post-traumatic stress disorder (PTSD). The underlying mechanisms, however, remain unknown. Because glucocorticoid receptor signaling is known to regulate emotional memory processes, particularly in men, epigenetic modifications of NR3C1 might affect the strength of traumatic memories. Here, we found that increased DNA methylation at the NGFI-A (nerve growth factor-induced protein A) binding site of the NR3C1 promoter was associated with less intrusive memory of the traumatic event and reduced PTSD risk in male, but not female survivors of the Rwandan genocide. NR3C1 methylation was not significantly related to hyperarousal or avoidance symptoms. We further investigated the relationship between NR3C1 methylation and memory functions in a neuroimaging study in healthy subjects. Increased NR3C1 methylation—which was associated with lower NR3C1 expression—was related to reduced picture recognition in male, but not female subjects. Furthermore, we found methylation-dependent differences in recognition memory-related brain activity in men. Together, these findings indicate that an epigenetic modification of the glucocorticoid receptor gene promoter is linked to interindividual and gender-specific differences in memory functions and PTSD risk.

Key words: DNA methylation; GR; memory; PTSD

Introduction

Post-traumatic stress disorder (PTSD) is characterized by intrusive memories of traumatic events, avoidance, and hyperarousal symptoms [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), American Psychiatric Association, 2000]. In contrast to a state of chronic stress, PTSD is not paralleled by increased glucocorticoid levels (Mcewisse et al., 2007), but rather by enhanced hypothalamus–pituitary–adrenal (HPA) axis feedback (Yehuda, 2002; Rohleder et al., 2004; Pitman et al., 2012). Moreover, there is evidence suggesting that altered HPA axis regulation and a high number of glucocorticoid receptors (GRs) represent a pretrauma risk factor for the disorder (Yehuda, 2009; van Zuiden et al., 2011, 2013). The reason for interindividual differences in GR number and the mechanism by which GRs influence the risk for PTSD, however, remain largely unknown.

Timed activation of GRs is of crucial importance in memory consolidation of learned information, especially of emotionally arousing information (Roozendaal et al., 2006). Human studies have shown that the memory-enhancing effects of stress-induced elevations of glucocorticoids are usually more pronounced in men (Andreano and Cahill, 2006; Preuss and Wolf, 2009; Corneille et al., 2011). Furthermore, there is evidence that glucocorticoids impair the retrieval of memory processes (de Quervain et al., 2009). Because fear learning and memory processes play an
important role in the pathogenesis of PTSD (de Quervain et al., 2006; Brewin, 2011; Pitman et al., 2012; Wilker et al., 2013). GRs may be implicated in PTSD risk by influencing memory processes (de Quervain et al., 2009). Accordingly, it has been shown that the Bcll polymorphism of NR3C1 (nuclear receptor subfamily 3, group C, member 1), the gene encoding the GR, is associated with sensitivity to glucocorticoids (van Rossum et al., 2003), emotional memory in healthy individuals (Ackermann et al., 2013), traumatic memories and PTSD symptoms in critically ill patients (Hauer et al., 2011).

Epigenetic mechanisms may contribute to interindividual differences in GR signaling. DNA hypermethylation of the exon NR3C1-1, promoter in rodents and of its human ortholog, the exon NR3C1-1, promoter (Turner and Muller, 2005), was associated with low maternal care, maternal depression, and perinatal stress (Weaver et al., 2007; Oberlander et al., 2008). In line with the enhanced GR feedback reported in PTSD cases (Yehuda, 2007), it has been shown that increased NR3C1 expression in peripheral tissue is related to PTSD risk (van Zuiden et al., 2011). Furthermore, it appears that these changes are partially epigenetically controlled. Two recent studies suggested that DNA methylation of the GR gene promoter are inversely correlated with lifetime PTSD risk (Labonté et al., 2014; Yehuda et al., 2014). Moreover, allele-specific DNA demethylation of FKBP5, a regulator of the GR complex, has been found to mediate gene–childhood trauma interactions (Klenget al., 2013).

Given the evidence that GR signaling influences both memory processes and PTSD risk, we investigated whether epigenetic differences in the human NR3C1 gene promoter are related to traumatic memory and the risk for PTSD in 152 survivors of the Rwandan genocide. Furthermore, we investigated the relationship of NR3C1 promoter DNA methylation with memory processes in a functional neuroimaging study in 72 healthy subjects.

Materials and Methods

Subjects: Rwanda sample. We included 152 survivors from the 1994 Rwandan genocide (69 females, 83 males; median age, 35 years; range, 30–41 years) who lived as refugees in the Nakivale settlement in Uganda. The sample consisted of 93 subjects fulfilling the diagnostic criteria of the DSM-IV for lifetime PTSD, and 59 individuals who did not meet the DSM-IV diagnostic criteria for PTSD (61.2% with PTSD lifetime diagnosis; 31.2% subjects with current PTSD according to DSM-IV (American Psychiatric Association, 2000). Additionally, to exclude genetic relatives in the samples, only one person per household was interviewed. Candidates exhibiting current alcohol abuse and acute psychiatric symptoms were excluded. All subjects had experienced highly aversive traumatic situations and were examined in 2006/2007 (de Quervain et al., 2007). The Post-Traumatic Diagnostic Scale (PDS; Foa et al., 1997) and event list (Ertl et al., 2010) were administered as a structured interview by expert psychologists from the University of Konstanz, Germany, as well as by trained local interviewers. Interviewers first went through a six-week course on principles of quantitative data collection and interviewing techniques. The translation of the instruments into Kinyarwanda was done using several steps of translations, blind back-translations, and subsequent corrections by independent groups of translators (Neuner et al., 2008). Following the translations, the psychometric properties of the translated scales were investigated in a validation study that included a retest spanning a two-week period and a cross-validation with expert rating (Neuner et al., 2008). The PDS was used to assess intrusions, avoidance, and hyperarousal. A checklist of 36 war-related and nonwar-related traumatic event types (e.g., injury by weapon, rape, accident) was used to assess traumatic events (de Quervain et al., 2007; Neuner et al., 2008). Traumatic load was estimated by assessing the number of different traumatic event types experienced or witnessed. This measure is considered more reliable than assessing the frequency of traumatic events (Neuner et al., 2008). Study procedures were approved by the ethics committees of the University of Konstanz, Germany, and the Mbarara University of Science and Technology, Mbarara, Uganda. Before the interview, all participants provided written informed consent.

Subjects were selected to have experienced ≥19 traumatic event types, to avoid known ceiling effects on PTSD risk (Kolassa et al., 2010). Saliva samples from all subjects were collected using Oragene DNA Kits (DNA Genotek). Subjects: Swiss sample. A total of 72 healthy young subjects (47 females, 25 males; median age, 23 years; range, 18–34 years) were included in the functional magnetic resonance imaging (fMRI) study. fMRI data from one male and two female subjects were corrupted and therefore were not included in the study. Subjects were free of any neurological or psychiatric illness, and did not take any medication at the time of the experiment (except hormonal contraceptives). The ethics committees of the Canton of Basel and Baselland approved the experiments.

Subjects were tested in the late morning and afternoon hours (mean time, 2:30 P.M.; SD ± 3 h). All participants received general information about the study and gave their written informed consent for participation. After completing the training outside of the scanner, subjects performed two different consecutive tasks in the scanner. The first two tasks, i.e., the picture-encoding task and the working-memory task (n-back), were described in detail previously (de Quervain et al., 2007). In summary, stimuli in the picture-encoding task consisted of 72 pictures selected from the International Affective Picture System (Lang et al., 1999) as well as from in-house standardized picture sets that allowed us to equate the pictures for visual complexity and content (e.g., human presence). On the basis of normative valence scores (from 1 to 9), pictures were assigned to emotionally negative (2.3 ± 0.6), emotionally neutral (5.0 ± 0.3), and emotionally positive (7.6 ± 0.4) conditions, resulting in 24 pictures for each emotional valence. Four additional pictures showing neutral objects were used to control for primacy and recency effects in memory. Two of these pictures were presented in the beginning and two at the end of the picture task and the working memory task. In addition, 24 scrambled pictures were used. The background of the scrambled pictures contained the color information of all pictures used in the experiment (except primacy and recency pictures), overlaid with a crystal and distortion filter (Adobe Photoshop CS3). In the foreground, a mostly transparent geometrical object (rectangle or ellipse of different sizes and orientations) was shown. Participants were instructed and then trained on the picture-encoding task. After training, they were positioned in the scanner. The picture-encoding task, which included the arousal and valence ratings of the pictures, lasted for ~20 min. Immediately afterward, subjects performed the working-memory task for 10 additional minutes. After leaving the scanner, participants gave a free recall of the pictures in a separate room (no time limit was set for this task). Forty to 50 min after the presentation of the last picture in the encoding task, participants were repositioned in the scanner and performed a recognition task for 20 min. The recognition task consisted of two sets of stimuli that were either new (i.e., not presented before) or old (i.e., presented during the picture-encoding task). Each of the two sets contained 72 pictures (24 pictures for each emotional valence).

Using an Oragene DNA and Oragene RNA Kit (DNA Genotek), saliva samples were collected from all subjects. Participants received 25 Swiss francs per hour for participation.

DNA isolation and bisulfite conversion. Saliva DNA was initially extracted from the Oragene DNA Kit (DNA Genotek) using the precipitation protocol recommended by the producer. To obtain high-purity DNA before bisulfite conversion, samples were additionally repurified. For this purpose, 2 μg of DNA isolated via the Oragene recommended procedure, was incubated overnight at 50°C with proteinase K (lysis buffer: 30 mls Tris-CI, 10 mls EDTA, 1% SDS, pH ~8.0, 150 ng/μl proteinase K), agitated by gentle orbital shaking. Next, the DNA was purified using a Genomic DNA Clean & Concentrator Kit (Zymo Research). The quality and concentration were assessed using gel electrophoresis and fluorometry (Qubit dsDNA BR Assay Kit, Invitrogen), respectively. Five hundred nanograms of high-purity, intact DNA was used for bisulfite conversion using an EZ DNA Methylation-Gold kit (Zymo Research) by following standard protocols. Bisulfite DNA quality
and concentration was determined using an RNA Pico 6000 Kit on a Bioanalyzer 2100 instrument (Agilent Technologies) and Nanodrop 2000 (ThermoScientific). An external control sample was always converted in parallel to assess possible variations in conversion reactions. All samples were bisulfite converted on two separate occasions, under the identical conditions. Bisulfite-converted (BSC) samples were normalized to 10 ng/μl. All samples were analyzed in quadruplicates from two independent bisulfite conversions.

Pyrosequencing analysis. The DNA methylation status of the CpG-rich region of the human NR3C1 gene, including the exon 1F promoter (NR3C1-1F) with the NFGF-A binding site, previously reported as important for epigenetic regulation of GR gene expression (Weaver et al., 2004), was quantified by direct bisulfite pyrosequencing (Test and Gut, 2007). Primers were designed according to recommendations of Wojdacz et al. (2009); NR3C1_Q-CpG_FW, 5′-GGTATTGTGAGGTTTGG-3′ and NR3C1_Q-CpG_RV, 5′-biot-CACCTCCCAAAAAAAA A-3′ (Microsynth). A 206 bp NR3C1 promoter fragment was amplified using an AmplyTaq Gold Kit from Applied Biosystems (Life Technologies). PCR was done in 30 μl reactions containing the following: 1X PCR buffer II, 300 μM deoxynucleotide triphosphates, final 3.5 mM MgCl2, 200 μM of each primer, 20 ng of BSC DNA. We used the following cycling conditions: 50°C × (95°C, 30 s; 55°C, 30 s; 72°C, 30 s) × 10 min. PCR products were purified and sequenced using a PyroMark ID System (Biotage) following the manufacturer’s suggested protocol and two sequencing primers: NR3C1_S2, 5′-GAGTGGTTGAGGTTTGG-3′ and NR3C1_S3, 5′-AGAAAAGAAATTGGAGAAATT-3′ (Microsynth). Testing for PCR temperature bias and calibration was done by introducing a series of calibrator samples with known methylation levels. Briefly, we prepared unmethylated standards by using two rounds of linear whole-genome amplification with an Ovation WGA System Kit (Nugenec), starting from 10 ng of DNA, as recommended by the manufacturer. Methylated standards were made using CpG methyltransferase assay with M.SssI (New England Biolabs) starting from 2 μg of purified DNA, following the standard protocol. Bisulfite conversion of standard samples was done as described above.

RNA isolation and expression analysis. For the purpose of DNA methylation–RNA expression correlation experiments, an additional 24 (12 females, 12 males; median age, 25 years; range, 21–29 years) subjects were included. RNA was isolated from Oragene RNA Self-Collection Kits from saliva. Promptly after collection, samples were mixed for 10 s by vortexing, stabilized at 30°C in a water bath for 2.5 h, and stored at ~80°C until further analysis. For the isolation procedure, samples were processed in 250 μl aliquots. Briefly, samples were incubated in a water bath at 90°C for 15 min, and then cooled to room temperature. Following this, 750 μl of TRIReagent LS (Ambion, Life Technologies) was added to each sample and homogenization was done for 1 min at 28 Hz using TissueLyser II (Qiagen). After homogenization, 1000 μl of absolute ethanol was added to the sample and mixed. Finally, the mixture was loaded on a Zymo-Spin IIC column and RNA was further purified using a Direct-zol kit (ZymoResearch) following the recommended procedure, including DNase I treatment.

The concentration and quality of the RNA was determined using Nanodrop 2000 (ThermoScientific) and a RNA Nano 6000 Kit on a Bioanalyzer 2100 instrument (Agilent). For reverse transcription, 350 ng of total RNA was denatured for 8 min at 70°C followed by ice incubation in the presence of 25 ng of anchored oligo(dt)20 primer (Invitrogen) and 75 ng of random decamers primers (Ambion). In the reverse transcription reaction, cDNA was generated in 25 μl reaction using a Super RT kit (HT Biotechnology). Upon completion of the reaction, the volume was adjusted to 200 μl in Lambda DNA solution (5 ng/μl final concentration; Promega). The primers were designed against splice variants that contain exon 1F of the NR3C1 gene: NR3C1_1F_FW, 5′-CGTACGTCGTAGTCAAGA-3′ and NR3C1_1F_RV, 5′-CCGTTGCGTCTC-3′. The primers were: 1F_FW, 5′-CCGTTGCGTCTC-3′ and NR3C1_1F_RV, 5′-CCGTTGCGTCTC-3′ (Microsynth). Additionally, total expression of the GR gene was determined against exon 2: NR3C1_2_FW, 5′-GACTCTCTACGTCGTCAAGA-3′ and NR3C1_2_RV, 5′-GACTCTCTACGTCGTCAAGA-3′ (Microsynth). The expression levels were normalized to the RPLPO gene (human large ribosomal protein) using the following primers: RPLP0-Ex3-4_FW, 5′-CTCTGGAGGAAGGCTGCTGC-3′ and RPLP0-Ex3-4_RV, 5′-CTGATCTCAGGAGGAGTTCG-3′ (Sigma–Aldrich). qPCR was performed using the Power SYBR Green PCR Master Mix (Life Technologies) according to standard recommendations, in 12 μl final volume of reaction, using 2 μl of cDNA template, on a Rotorgene 6000A instrument (Corbett Research). Cycling conditions were as follows: 95°C, 60 s–40°C (95°C, 3 s; 55°C, 30 s; 72°C, 4 s). This was followed by a melting curve analysis (61–95°C, rising by 0.7°C/3 s) to attest amplification specificity. Threshold cycles (crossing point) were determined using Rotor-Gene Software version 6.1 (Corbett Research). RPLPO was selected as reference gene for normalization after we tested several candidate reference genes, as had been previously described (Mowassagh et al., 2010). Expression levels were normalized using a geometric mean level of expression (Vandesompele et al., 2002). Fold differences were calculated using the delta-delta-Ct method (Pfaffl, 2001) with the help of qBasePlus software (Biogazelle).

fMRI study design. During the encoding task, the pictures were presented for 2.5 s in a quasirandomized order so that ≤4 pictures of the same category occurred consecutively. A fixation cross appeared on the screen for 500 ms before each picture presentation. Trials were separated by a variable intertrial period of 9–12 s (jitter) that was equally distributed for each stimulus category. During the intertrial period, participants were encouraged not to look at the scene. Scenes were split into three basic categories—positive, neutral, and negative. The first category included happy scenes (happy, joyful, or excitement); the second category included neutral scenes (neutral, not active, positive, or neutral and arousal (high, medium, and low)) on a three-point scale (self-assessment manikin) by pressing a button with a finger of their dominant hand. For scrambled scenes, participants rated form (vertical, symmetric, or horizontal) and size (large, medium, small) of the geometrical object in the foreground.

During the recognition task, the pictures were presented for 1 s in a quasirandomized order so that ≤4 pictures of the same category (i.e., negative new, negative old, neutral new, neutral old, positive new, positive old) occurred consecutively. A fixation cross appeared on the screen for 500 ms before each picture presentation. Trials were separated by a variable intertrial period of 6–12 s (jitter) that was equally distributed for each stimulus category. During the intertrial period, participants subjectively rated the picture as either remembered, familiar, or new on a three-point scale by pressing a button with a finger of their dominant hand. Recognition performance was assessed as a number of correctly recognized previously seen pictures, corrected for the number of false positives.

fMRI methods. Measurements were performed on a Siemens Magnetom Verio 3 T whole-body MR unit equipped with a 12-channel head coil (Siemens Healthcare). Functional time series were acquired with a single-shot echo-planar sequence using parallel imaging [GRAPPA (generalized autocalibrating partially parallel acquisition)]. We used the following acquisition parameters: TE, 35 ms; field of view, 22 cm; acquisition matrix, 80 × 80, interpolated to 128 × 128; voxel size, 2.75 × 2.75 × 4 mm3; GRAPPA acceleration factor r, 2.0. Using a mid sagittal scout image, 32 contiguous axial slices placed along the anterior–posterior commissure plane covering the entire brain with a TR = 3000 ms (α = 82°) were acquired using an ascending interleaved sequence.

Participants received earplugs and headphones to reduce scanner noise. The head of each participant was fixated in the coil using small cushions, and participants were told not to move their head. Pictures were presented in the scanner using MR-compatible liquid crystal display goggles (VisualSystem; NordicNeuroLab). Eye correction was used when necessary.

Preprocessing and data analysis was performed using SPM8 (Statistical Parametric Mapping, Wellcome Trust Centre for Neuroimaging; http://www.fil.ion.ucl.ac.uk/spm/) implemented in Matlab R2011b (Mathworks). Volumes were slice-time corrected to the first slice and realigned using the “register to mean” option. A mean image was generated from the realigned series and coregistered to the structural image. This ensured that functional and structural images were spatially aligned. Subject individual functional image and structural images were spatially normalized by applying DARTEL (diffeomorphic anatomical registration through exponentiated lie algebra), which leads to an improved registration between subjects. Normalization incorporated the following steps: (1) structural images of each subject were segmented using the “New
Segmentation procedure in SPM8; (2) the resulting grey and white matter images were used to derive a study-specific group template computed from a large population of 612 subjects, including the 69 subjects from this study where methylation data were available; (3) an affine transformation was applied to map the group template to MNI space; and (4) subject-to-template and template-to-MNI transformations were combined to map the functional images to MNI space. The functional images were smoothed with an isotropic 8 mm full width at half maximum Gaussian filter.

Intrinsic autocorrelations were accounted for by AR(1) and low-frequency drifts were removed via high-pass filter (time constant, 128 s). For each subject, evoked hemodynamic responses to event types were modeled with a delta function convolved with a canonical hemodynamic response function within the context of a general linear model. Button presses and rating scale presentation during ratings were modeled separately. In addition, six movement parameters from spatial realignment were included as regressors of no interest.

Encoding task: The effect of picture encoding was investigated by constructing separate regressors representing the event types for positive, negative, neutral, and scrambled pictures. We contrasted brain activity during the encoding of pictures against brain activity during the presentation of scrambled pictures (positive, negative, and neutral pictures vs scrambled pictures).

Recognition task: Eighteen different picture event types were modeled by crossing each stimulus category with the subject-specific rating of each picture while differentiating between correct and incorrect recognition ratings with respect to the new or old picture set: (negative, positive, neutral) × (remembered, familiar, new) × (correct, incorrect). We contrasted brain activity between items that were correctly recognized as seen before and new pictures (i.e., pictures seen in the encoding task and rated as remembered vs pictures not seen before and rated as new). Items rated as familiar were not included in the analysis.

The contrasts of both the encoding and the recognition task were calculated individually using a fixed-effects model (first-level analysis). The resulting contrast parameters were then used for methylation-dependent brain activity analyses in a random-effects, linear regression model where we entered the methylation level as a covariate (second-level analysis).

Construction of a population-average anatomical probabilistic atlas. Automatic segmentation of the subjects’ T1-weighted images was used to build a population-average probabilistic anatomical atlas. More precisely, each participant’s T1-weighted image was first automatically segmented into cortical and subcortical structures using FreeSurfer (Fischl et al., 2002; version 4.5, http://surfer.nmr.mgh.harvard.edu/). Labeling of the cortical gyrus was based on the Desikan-Killiany Atlas (Desikan et al., 2006), yielding 35 regions per hemisphere.

The segmented T1 image was then normalized to the study-specific anatomical template space using the subject’s previously computed warp field. After this, the image was affine-registered to the MNI space. Nearest-neighbor interpolation was applied to preserve labeling of the different structures. The normalized segmentations were finally averaged across subjects to create a population-average probabilistic atlas. Each voxel of the template could consequently be assigned a probability of belonging to a given anatomical structure, based on the individual information from all subjects.

Statistical analyses. Statistical analyses were done in R (version 2.15.2; R Development Core Team 2012). Due to non-normal distribution of methylation data in the Rwanda sample, we applied nonparametric tests. We assessed DNA methylation, trauma load, and age differences between two genders by Kruskal–Wallis one-way ANOVA and correlations of DNA methylation data with PTSD symptom clusters scores by Spearman’s rank correlation (p). To account for trauma load and ceiling effects (Kolassa et al., 2010), PTSD symptom cluster scores were divided by the sum of lifetime traumatic event types (i.e., symptoms scores per traumatic event type; de Quervain et al., 2007). The relationship between DNA methylation at NR3C1 promoter and lifetime PTSD status was assessed using binary logistic regression, with NR3C1 CpG3 DNA methylation as quantitative predictor and the sum of lifetime traumatic event types as a covariate.

Due to normal distribution of the methylation data, statistical analyses of behavioral data for the Swiss sample were performed using linear models. The relationship of NR3C1 DNA methylation to memory performance and NR3C1 expression was assessed using linear models. To account for methylation-dependent differences in arousal during recognition of previously seen pictures, both arousal and NR3C1 CpG3 DNA methylation were included in the linear model: we modeled valence-specific recognition performance as dependent on NR3C1 CpG3 DNA methylation and valence-specific arousal.

Correlation between NR3C1 CpG3 DNA methylation and NR3C1 expression was examined by linear regression model, corrected for age independently in two genders.

A comparison of methylation levels of NR3C1 CpG3 site between the Rwandan and the Swiss population was done by Kruskal–Wallis one-way ANOVA. Furthermore, we additionally assessed the equality of distributions and variance between two populations: Kolmogorov–Smirnov two-sample test and Siegel–Tukey test, respectively.

Bonferroni correction was implemented to account for multiple testing procedures. The significance threshold was set to p < 0.05.

All laboratory procedures were conducted in a blind, randomized order, including DNA and RNA isolations, bisulfite conversion, PCR, pyrosequencing, and expression analysis. Only after performing all procedures and excluding samples with low quality controls and outliers, further analysis with phenotypic data was performed.

Results
DNA methylation of the NR3C1 promoter in traumatized survivors of the Rwandan genocide.

The promoter region of the NR3C1 gene studied herein is illustrated in Figure 1. It spans the exon 1F region, a human orthologue of the rat exon 1-7 (Turner and Muller, 2005), previously reported as differentially methylated (Oberlander et al., 2008; McGowan et al., 2009). The analysis covered eight CpGs, with the NGFI-A consensus binding sequence encompassing CpG positions 3 and 4. Because glucocorticoid-related changes in memory formation were repeatedly found to be more pronounced in men (Andreano and Cahill, 2006; Preuss and Wolf, 2009), we also considered possible gender differences in the present study. We first compared DNA methylation between genders and found significant differences between men and women at several CpG positions (p < 0.05, e.g., methylation levels at NR3C1_CpG3 and...
were significantly higher in women than in men, \( p = 0.01 \). Therefore, we proceeded with gender-specific analyses. To account for trauma load, PTSD symptom cluster scores were corrected by the sum of lifetime traumatic event types (de Quervain et al., 2007). Methylation levels at the CpG3 site, which is embedded in the NGFI-A consensus binding sequence, were significantly negatively correlated with the severity of symptoms related to re-experiencing traumatic events (intrusive memories) in men (\( \rho_s = -0.355 \), \( P_{\text{Bonferroni corrected}} = 0.008 \) for eight CpG comparisons; Fig. 2, Table 1). No such association was found in women (\( \rho_s = -0.073 \), \( P_{\text{Bonferroni corrected}} = 0.553 \); Table 2). Correlations of DNA methylation at CpG3 with the severity of symptoms related to avoidance and hyperarousal were not significant after Bonferroni correction for eight CpGs (\( p > 0.05 \)), indicating that the methylation changes at this site were preferentially related to the memory aspects of PTSD.

Furthermore, we investigated whether methylation levels at CpG3 were significantly associated with lifetime PTSD risk (taking into account the total number of experienced traumatic event types; see Materials and Methods). We found that higher methylation levels were significantly associated with a lower lifetime PTSD risk in men (\( \beta = -0.519 \), Wald \( \chi^2 = 7.0 \), \( p = 0.008 \); Fig. 3), but not in women (\( \beta = -0.170 \), Wald \( \chi^2 = 1.4 \), \( p = 0.243 \); Fig. 3). Interindividual differences in methylation levels at CpG3 were not significantly associated with the number of traumatic life event types (\( p = 0.23 \) and 0.76 for men and women, respectively). Furthermore, age was not significantly associated with DNA methylation in either gender (\( p = 0.10 \) and 0.14 for men and women, respectively).

DNA methylation at the NR3C1 promoter, memory performance, and fMRI activity during picture recognition

Because in genocide survivors NR3C1 CpG3 methylation was strongly associated with the intrusive memory aspect of PTSD and given the role of glucocorticoid signaling in memory processes (de Quervain et al., 2009), we further examined the
Table 1. Association of PTSD symptom clusters and DNA methylation of NR3C1 gene promoter in Rwandan men

<table>
<thead>
<tr>
<th>PTSD symptom clusters (n_{males} = 83)</th>
<th>NR3C1_CpG1</th>
<th>NR3C1_CpG2</th>
<th>NR3C1_CpG3</th>
<th>NR3C1_CpG4</th>
<th>NR3C1_CpG5</th>
<th>NR3C1_CpG6</th>
<th>NR3C1_CpG7</th>
<th>NR3C1_CpG8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intrusions</td>
<td>Spearman’s $\rho$</td>
<td>$-0.235$</td>
<td>$-0.039$</td>
<td>$-0.355$</td>
<td>$-0.128$</td>
<td>$-0.203$</td>
<td>$-0.059$</td>
<td>$-0.118$</td>
</tr>
<tr>
<td></td>
<td>$p$ value</td>
<td>Nominal</td>
<td>$0.037^*$</td>
<td>$0.733$</td>
<td>$0.001^{***}$</td>
<td>$0.261$</td>
<td>$0.073$</td>
<td>$0.606$</td>
</tr>
<tr>
<td></td>
<td>Bonferroni correction for 8 CpGs</td>
<td>$0.296$</td>
<td>$1$</td>
<td>$0.008$</td>
<td>$1$</td>
<td>$0.584$</td>
<td>$1$</td>
<td>$1$</td>
</tr>
<tr>
<td></td>
<td>Bonferroni correction for 8 CpGs, sex, and 3 PTSD symptom clusters</td>
<td>$1$</td>
<td>$1$</td>
<td>$0.048$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
</tr>
<tr>
<td>Avoidance</td>
<td>Spearman’s $\rho$</td>
<td>$-0.115$</td>
<td>$-0.033$</td>
<td>$-0.260$</td>
<td>$-0.033$</td>
<td>$-0.101$</td>
<td>$-0.049$</td>
<td>$-0.019$</td>
</tr>
<tr>
<td></td>
<td>$p$ value</td>
<td>Nominal</td>
<td>$0.315$</td>
<td>$0.772$</td>
<td>$0.021^*$</td>
<td>$0.77$</td>
<td>$0.376$</td>
<td>$0.666$</td>
</tr>
<tr>
<td></td>
<td>Bonferroni correction for 8 CpGs</td>
<td>$1$</td>
<td>$1$</td>
<td>$0.168$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
</tr>
<tr>
<td></td>
<td>Bonferroni correction for 8 CpGs, sex, and 3 PTSD symptom clusters</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
</tr>
<tr>
<td>Hyperarousal</td>
<td>Spearman’s $\rho$</td>
<td>$-0.187$</td>
<td>$-0.097$</td>
<td>$-0.346$</td>
<td>$-0.038$</td>
<td>$-0.165$</td>
<td>$-0.074$</td>
<td>$-0.08$</td>
</tr>
<tr>
<td></td>
<td>$p$ value</td>
<td>Nominal</td>
<td>$0.099$</td>
<td>$0.396$</td>
<td>$0.009^{**}$</td>
<td>$0.74$</td>
<td>$0.145$</td>
<td>$0.514$</td>
</tr>
<tr>
<td></td>
<td>Bonferroni correction for 8 CpGs</td>
<td>$0.792$</td>
<td>$1$</td>
<td>$0.072$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
</tr>
<tr>
<td></td>
<td>Bonferroni correction for 8 CpGs, sex, and 3 PTSD symptom clusters</td>
<td>$1$</td>
<td>$1$</td>
<td>$0.432$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
</tr>
<tr>
<td>PDS score$^{a,b,c}$</td>
<td>Spearman’s $\rho$</td>
<td>$-0.207$</td>
<td>$-0.056$</td>
<td>$-0.355$</td>
<td>$-0.081$</td>
<td>$-0.172$</td>
<td>$-0.036$</td>
<td>$-0.078$</td>
</tr>
<tr>
<td></td>
<td>$p$ value</td>
<td>Nominal</td>
<td>$0.067$</td>
<td>$0.627$</td>
<td>$0.001^{***}$</td>
<td>$0.476$</td>
<td>$0.131$</td>
<td>$0.756$</td>
</tr>
<tr>
<td></td>
<td>Bonferroni correction for 8 CpGs</td>
<td>$0.536$</td>
<td>$1$</td>
<td>$0.008$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
</tr>
<tr>
<td></td>
<td>Bonferroni correction for 8 CpGs, sex, and 3 PTSD symptom clusters</td>
<td>$1$</td>
<td>$1$</td>
<td>$0.048$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
<td>$1$</td>
</tr>
<tr>
<td>NR3C1 DNA methylation</td>
<td>Mean</td>
<td>$2.86$</td>
<td>$1.52$</td>
<td>$2.84$</td>
<td>$1.01$</td>
<td>$1.77$</td>
<td>$3.52$</td>
<td>$4.88$</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>$1.32$</td>
<td>$1.55$</td>
<td>$1.56$</td>
<td>$1.45$</td>
<td>$1.58$</td>
<td>$1.81$</td>
<td>$1.82$</td>
</tr>
</tbody>
</table>

$^a$Correlation of NR3C1 gene promoter DNA methylation with sum of PTSD-specific symptom subscores according to PDS and DSM-IV. To account for trauma load, PTSD symptom cluster scores were divided by the sum of lifetime traumatic event types. Spearman’s correlation $\rho$, coefficients and the corresponding nominal and Bonferroni-corrected $p$ values are shown for each symptom cluster.

$^b$Sum of specific symptom clusters corrected for total number of lifetime traumatic events.

$^c$PDS score is not an additional symptom measure, as it represents the sum of the subscores of Intrusions, Avoidance, and Hyperarousal.

$^{***}$Correlation is nominally significant at the 0.001 level (2-tailed, Spearman’s $\rho$).

$^{**}$Correlation is nominally significant at the 0.01 level (2-tailed, Spearman’s $\rho$).

$^*$Correlation is nominally significant at the 0.05 level (2-tailed, Spearman’s $\rho$).

The relationship of NR3C1 DNA methylation variation to memory processes in healthy humans. Specifically, we investigated whether NR3C1 CpG3 methylation levels in healthy individuals were associated with memory performance and brain activation during a picture-recognition task in the fMRI scanner.

NR3C1 CpG3 DNA methylation was negatively correlated with the correct recognition of previously seen pictures in men but not in women (men: $\beta = -0.455$, $p = 0.012$; women: $\beta = -0.065$, $p = 0.667$; Table 3). Furthermore, DNA methylation at this site in men was significantly associated with arousal during encoding of negative pictures, but not of neutral or positive pictures (Table 3). After correcting for the valence-specific arousal rating, recognition of previously seen pictures was significantly negatively correlated with NR3C1 CpG3 DNA methylation independently of the valence category in men but not in women (Table 3). Free-recall performance was not related to methylation levels at NR3C1 CpG3 (men: $\beta = -0.291$, $p = 0.16$; women: $\beta = -0.048$, $p = 0.74$).

Next, we performed a methylation-dependent fMRI analysis during successful memory recognition (see Materials and Methods). In men, we found a whole-brain, family-wise error (FWE) multiple-comparison corrected ($p_{\text{FWER}} < 0.05, p_{\text{uncorrected}} < 0.001$) positive correlation between methylation levels at the CpG3 site of the NR3C1 promoter and brain activity related to the successful recognition of previously seen pictures in the pars triangularis and pars orbitalis of the inferior frontal gyrus, in the cuneus, and in the vicinity of the superior temporal and superior frontal cortices (Fig. 4, Table 4). No voxels correlated significantly with methylation values in the opposite direction. We did not observe significant associations between methylation levels at the CpG3 site and brain activity in females. Moreover, we did not find significant correlations of individual methylation levels with encoding-related brain activity.

Finally, we compared methylation levels of NR3C1 promoter CpG3 site between the Rwandan and the Swiss sample. Importantly, we did not find a significant difference in median, distribution, or variability between the samples (Kruskal–Wallis $\chi^2 = 1.392, p = 0.24$; Kolmogorov–Smirnov $D = 0.150, p = 0.22$; Siegel–Tukey $W = 4829.5, p = 0.29$). These findings suggest that methylation at this specific site is a stable trait and likely pre-existed the traumatic event in the Rwandan population.

Expression of the GR gene and DNA methylation at the NR3C1 gene promoter

Finally, we tested whether DNA methylation on the CpG3 site of the NR3C1 promoter was associated with NR3C1 gene expression in a subset of 24 healthy (12 females and 12 males) subjects. DNA methylation at the CpG3 site correlated significantly with both
Table 2. Association of PTSD symptom clusters and DNA methylation of NR3C1 gene promoter in Rwandan women

<table>
<thead>
<tr>
<th>PTSD symptom clusters (n_{males} = 69)</th>
<th>NR3C1_CpG1</th>
<th>NR3C1_CpG2</th>
<th>NR3C1_CpG3</th>
<th>NR3C1_CpG4</th>
<th>NR3C1_CpG5</th>
<th>NR3C1_CpG6</th>
<th>NR3C1_CpG7</th>
<th>NR3C1_CpG8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intrusions(a)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spearman's (p)</td>
<td>-0.166</td>
<td>0.013</td>
<td>-0.073</td>
<td>0.037</td>
<td>0.065</td>
<td>0.033</td>
<td>-0.071</td>
<td>0.019</td>
</tr>
<tr>
<td>p value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nominal correction for 8 CpGs</td>
<td>0.173</td>
<td>0.916</td>
<td>0.553</td>
<td>0.763</td>
<td>0.598</td>
<td>0.785</td>
<td>0.561</td>
<td>0.876</td>
</tr>
<tr>
<td>Bonferroni correction for 8 CpGs, sex, and 3 PTSD symptom clusters</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Avoidance(b)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spearman's (p)</td>
<td>-0.116</td>
<td>-0.118</td>
<td>-0.139</td>
<td>0.006</td>
<td>-0.059</td>
<td>-0.058</td>
<td>-0.045</td>
<td>0.092</td>
</tr>
<tr>
<td>p value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nominal correction for 8 CpGs</td>
<td>0.344</td>
<td>0.333</td>
<td>0.256</td>
<td>0.063</td>
<td>0.633</td>
<td>0.635</td>
<td>0.714</td>
<td>0.45</td>
</tr>
<tr>
<td>Bonferroni correction for 8 CpGs, sex, and 3 PTSD symptom clusters</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Hyperarousal(b)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spearman's (p)</td>
<td>-0.003</td>
<td>-0.014</td>
<td>-0.052</td>
<td>0.003</td>
<td>0.002</td>
<td>-0.04</td>
<td>-0.057</td>
<td>-0.033</td>
</tr>
<tr>
<td>p value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nominal correction for 8 CpGs</td>
<td>0.983</td>
<td>0.912</td>
<td>0.672</td>
<td>0.667</td>
<td>0.99</td>
<td>0.746</td>
<td>0.642</td>
<td>0.79</td>
</tr>
<tr>
<td>Bonferroni correction for 8 CpGs, sex, and 3 PTSD symptom clusters</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>POS score(c)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spearman's (p)</td>
<td>-0.114</td>
<td>-0.046</td>
<td>-0.089</td>
<td>0.011</td>
<td>0.003</td>
<td>-0.006</td>
<td>-0.066</td>
<td>0.054</td>
</tr>
<tr>
<td>p value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nominal correction for 8 CpGs</td>
<td>0.352</td>
<td>0.706</td>
<td>0.469</td>
<td>0.928</td>
<td>0.982</td>
<td>0.959</td>
<td>0.605</td>
<td>0.657</td>
</tr>
<tr>
<td>Bonferroni correction for 8 CpGs, sex, and 3 PTSD symptom clusters</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>NR3C1 DNA methylation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>3.23</td>
<td>1.90</td>
<td>3.55</td>
<td>1.19</td>
<td>2.42</td>
<td>4.16</td>
<td>5.43</td>
<td>2.29</td>
</tr>
<tr>
<td>SD</td>
<td>1.62</td>
<td>1.81</td>
<td>1.85</td>
<td>1.59</td>
<td>1.83</td>
<td>2.32</td>
<td>1.96</td>
<td>1.90</td>
</tr>
</tbody>
</table>

\(a\)Correlation of NR3C1 gene promoter DNA methylation with sum of PTSD-specific symptom subscores according to POS and DSM-IV. To account for trauma load, PTSD symptom clusters scores were divided by the sum of lifetime traumatic event types. Spearman's correlation coefficients and the corresponding nominal and Bonferroni-corrected \(p\) values are shown for each symptom cluster.

\(b\)Mean of specific symptom clusters corrected for total number of traumatic events in a lifetime.

\(c\)POS score is not an additional symptom measure, as it represents the sum of the subscores of Intrusions, Avoidance, and Hyperarousal.

Figure 3. Fitted values of probability for lifetime PTSD risk against DNA methylation at the NGFI-A binding site of the NR3C1 promoter for males and females. Lifetime PTSD risk was assessed against NR3C1 CpG3 DNA methylation and the number of lifetime traumatic event types via binary logistic regression (\(n_{males} = 83, p_{nominal, males} = 0.008, \beta_{males} = -0.519, n_{females} = 69, p_{nominal, females} = 0.243, \beta_{females} = -0.170\)). This graph also contains the raw CpG methylation values obtained in participants without (bottom line) and with (top line) PTSD.
Discussion

The present study indicates that DNA methylation at the NR3C1 exon 1F promoter is linked to traumatic memories and PTSD risk in male, but not in female genocide survivors. These methylation differences are located at the NGFI-A transcriptional factor binding sequence and the methylation levels correlated negatively with the expression of NR3C1, indicating the functional relevance of the methylation status at this site.

Studies in rodents have shown that specific 5’NR3C1-1F promoter sites are targets of DNA methylation, leading to suppressed NGFI-A binding and consequently decreased NR3C1 gene expression (Weaver et al., 2007). DNA hypermethylation at these sites has been associated with low quality of received maternal care in adult male offspring (female offspring were not examined; Weaver et al., 2004), as well as prenatal stress exposure (Mueller and Bale, 2008). Hypermethylation at the human ortholog NR3C1-1F promoter NGFI-A binding site was likewise associated to perinatal stress and maternal depression (Oberlander et al., 2008). A recent study in male combat veterans reported that DNA methylation at NR3C1-1F in peripheral blood mononuclear cells was inversely correlated with PTSD risk, NR3C1 gene expression, cortisol decline in response to dexamethasone, and clinical measures of PTSD, including poorer sleep (Yehuda et al., 2014). Another study reported that DNA methylation of NR3C1-1B and NR3C1-1C promoters in sorted T-lymphocytes is also inversely correlated with PTSD risk and morning cortisol levels in individuals with different trauma background (Labonté et al., 2014).

Epigenetic marks at the NR3C1 locus are set during a sensitive period around birth and seem to remain stable throughout life in rodents (Weaver et al., 2004; Mueller and Bale, 2008; Suderman et al., 2012) and humans (Oberlander et al., 2008; McGowan et al., 2009; Radtke et al., 2011; Suderman et al., 2012). These findings suggest that, in the present study, NR3C1 methylation differences may have existed before the traumatic events. Alternatively, trauma exposure might have triggered mechanisms that lead to altered epigenetic patterns. In the present study, interindividual differences in methylation levels at the NR3C1-1F promoter were not related to traumatic load. Likewise, Yehuda et al. also reported no significant association between trauma exposure and NR3C1-1F promoter DNA methylation (Yehuda et al., 2014). Furthermore, we did not observe significant differences in medians and interindividual variability of NR3C1-1F promoter methylation between Rwandan genocide survivors and healthy individuals not exposed to trauma. Together, these findings suggest that the differences in methylation levels pre-existed the traumatic events, supporting the idea that alterations in the HPA axis regulation represent at least partially a pretrauma risk factor for the disorder (Yehuda, 2009; de Quervain et al., 2009). Pre-existing differences in DNA methylation at NR3C1 may be a result of interplay between selected types of early adversity and specific timing of exposure. They may also reflect other types of risks associated with the HPA axis inhibition (Yehuda, 2009). Finally, one possibility is that NR3C1-1F promoter DNA methylation differences are a result of development/early life-associated stochastic epigenetic variation leading to differences in disease susceptibility (Feinberg and Irizarry, 2010). Characterization of the causal pathways involved in epigenetic modifications and the relative stability and reversibility of such
changes require more research (Zhang et al., 2010; Hunter and McEwen, 2013).

Previous studies investigated epigenetic modifications associated with PTSD in peripheral blood (Chang et al., 2012; Klengel et al., 2013; Mehta et al., 2013; Labonté et al., 2014; Yehuda et al., 2014). In this study we used DNA isolated from saliva. The source of DNA in saliva is a mixture of ectodermal-origin epithelial cells and white blood cells (Zhou et al., 2011). Several studies suggest that DNA methylation signatures in genomic regions rich in cytosine-guanine dinucleotides (as it is the case with NR3C1-1F promoter) generally show stable epigenetic signatures across brain and nonbrain tissues (Ladd-Acosta et al., 2007; Mill et al., 2008; Lister et al., 2009; Dempster et al., 2011; Davies et al., 2012). Indeed, it has been shown that childhood adversity is related to NR3C1-1F promoter methylation both in peripheral tissue (Oberlander et al., 2008; Radtke et al., 2011) and in the brain (McGowan et al., 2009). Moreover, we have found that interindividual differences in methylation of the NR3C1-1F promoter in DNA isolated from saliva were associated with differences in brain activity. Together, these findings suggest that with regard to NR3C1-1F methylation, similar patterns may be present across tissues. Thus, it may be possible to a certain extent to use nonbrain tissue for the investigation of certain CNS traits, such as psychiatric disorders.

As expected, we found that increased DNA methylation at the NR3C1-1F promoter negatively correlated with expression of NR3C1. It is known that an acute and timed activation of GRs is crucially involved in memory formation (Roozendaal, 2000; Roozendaal et al., 2006). Thus, increased NR3C1 promoter methylation might be related to reduced memory formation, including traumatic memory after a traumatic event. Indeed, we found that increased NR3C1-1F CpG3 methylation was associated with less intrusive memory (genocide survivors) and less picture-recognition memory (healthy population), but only in males. It is unlikely that gender differences in methylation or expression may have accounted for the lack of relationship between methylation and memory in women, because the correlation between CpG3 methylation and NR3C1 expression was independent of gender. We hypothesize that the gender-specific findings reported herein occur post-transcriptionally, possibly reflecting gender-specific effects of glucocorticoids on memory. Indeed, the finding that NR3C1-1F methylation was related to memory only in men is in line with reports that found glucocorticoid effects on memory to be more pronounced in men than in women, or even restricted to men (Andreano and Cahill, 2006; Preuss and Wolf, 2009; Corneille et al., 2011). The reason for this gender-dependent difference in glucocorticoid effects is not well understood. A possible interaction between glucocorticoids and sex hormones has been proposed (Preuss and Wolf, 2009), and further efforts are necessary to address sex-related differences in glucocorticoid signaling and its molecular signatures.

The present findings point to a relationship of NR3C1-1F promoter methylation with memory processes also in healthy humans. Specifically, we found that methylation levels at the NR3C1-1F correlated negatively with recognition memory in men, but not in women. This relationship was independent of valence, which is in line with previous findings indicating that the memory-modulating effects of elevated glucocorticoid levels can also affect neutral material when the learning context is emotionally arousing (Preuss and Wolf, 2009). The neuroimaging findings indicated that male subjects with higher methylation levels had increased activation in the right ventrolateral prefrontal cortex (VLPFC) and the cuneus. Interestingly, the right VLPFC has been discussed as a brain region involved in retrieval attempt and effort rather than retrieval success (Taylor et al., 2004; Badre and Wagner, 2007), which is in line with the present finding of increased activation in this region in subjects with higher methylation levels and less successful recognition performance. Moreover, a recent meta-analysis has pointed to an involvement of the VLPFC in the neurocircuitry of PTSD (Hayes et al., 2012). Specifically, patients with PTSD show decreased activity in the inferior frontal gyrus compared with trauma-exposed controls without PTSD when reliving one’s traumatic event.

The relationship between glucocorticoids, memory, and PTSD is complex and not fully understood. Whereas high numbers of GRs before trauma have been found to be a risk factor for developing PTSD (van Zuiden et al., 2011), a pharmacological elevation of glucocorticoid levels during or after a traumatic event seems to prevent and reduce PTSD symptoms (Schelling et al., 2001, 2004; Aerni et al., 2004). This may have to do with differential effects of glucocorticoids depending on timing and the memory phase affected (de Quervain et al., 2009; Joëls et al., 2011). A timed activation of GRs is important for memory consolidation and may lead to strong aversive memories in case of a traumatic event. On the other hand, elevated glucocorticoid levels have been shown to impair memory retrieval of emotionally arousing information, which may lead to reduced traumatic memories (de Quervain et al., 2009). In addition to the glucocorticoid effects on emotional memory, evidence indicates that glucocorticoids can have effects on emotional processing: a recent study suggested that the presence of elevated levels of glucocorticoids at the time of acute stress confers protection against the delayed enhancing effect of stress on amygdala synaptic connectivity and anxiety-like behavior (Rao et al., 2012). Thus, altered glucocorticoid signaling may have differential effects on the development and symptoms of PTSD, depending on the emotional and cognitive processes affected.

In conclusion, we provide evidence that DNA methylation at the NR3C1-1F promoter is preferentially related to the memory aspects of PTSD symptomatology and PTSD risk in men. Moreover, we found that the same epigenetic modification was related to memory functions in healthy subjects, suggesting that this

<table>
<thead>
<tr>
<th>Maximum t value within cluster</th>
<th>Regional correspondence of the maximum</th>
<th>MNI coordinates at maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>6.4174</td>
<td>Cortex-right hemisphere-paris orbitals (36%), cortex-right hemisphere-paris triangularis (31%) of the inferior frontal gyrus</td>
<td>44</td>
</tr>
<tr>
<td>6.5307</td>
<td>Near superior temporal cortex</td>
<td>44</td>
</tr>
<tr>
<td>6.3278</td>
<td>Cortex-left hemisphere-cuneus (48%), cortex-left hemisphere-pericarline (10%)</td>
<td>0</td>
</tr>
<tr>
<td>6.4978</td>
<td>Near superior frontal cortex</td>
<td>19.25</td>
</tr>
</tbody>
</table>

*P<0.05, brain activity template.*
modification possibly affects traumatic memory and PTSD via a modulation of memory processes. The present findings may add to the understanding of individual PTSD risk factors and suggest that NR3C1 DNA methylation may represent a biological marker for traumatic memories and PTSD.

References


